ライフサイエンスコーパス: ixabepilone

1 s after paclitaxel and lesser deficits after ixabepilone.

2 Thirty-seven patients received 153 cycles of ixabepilone.

3 urred in tumor biopsies after treatment with ixabepilone.

4 had a taxane as their last regimen, received ixabepilone (1- or 3-hour infusion of 50 mg/m(2) or 3-ho

5 m A), nab-paclitaxel 150 mg/m(2) (arm B), or ixabepilone 16 mg/m(2) (arm C), once per week for 3 of 4

6 atment with each agent, received intravenous ixabepilone 20 mg/m(2) administered over 1 hour on days

7 CONCLUSION Ixabepilone 20 mg/m(2) over 1 hour on days 1, 8, and 15

8 ndomly assigned at a ratio of 1:1 to receive ixabepilone (32 mg/m(2)) and carboplatin (area under con

9 d phase II dose is mitoxantrone 12 mg/m2 and ixabepilone 35 mg/m2 every 21 days, pegfilgrastim 6 mg s

10 Patients were randomly assigned to receive ixabepilone (35 mg/m(2)) by intravenous infusion every 3

11 Patients received ixabepilone 40 mg/m(2) as a 3-hour infusion on day 1 of

12 fifty-two patients were randomly assigned to ixabepilone 40 mg/m(2) intravenously on day 1 of a 21-da

13 Ixabepilone 40 mg/m(2) monotherapy was administered as a

14 Ixabepilone (40 mg/m(2) as a 3-hour infusion every 3 wee

15 ycline and taxanes were randomly assigned to ixabepilone (40 mg/m(2) intravenously on day 1) plus cap

16 ced breast cancer patients were treated with ixabepilone (6 mg/m2) for 5 consecutive days every 3 wee

17 okinetics, and preliminary response rate for ixabepilone, a microtubule-stabilizing agent, administer

18 In general, ixabepilone administered as a single-agent and in combin

19 The MTD of ixabepilone administered daily for 5 days every 21 days

20 lled and randomly assigned to treatment with ixabepilone alone (45 patients) or in combination with E

21 .4 months (95% CI, 3.1 to 6.9 months) on the ixabepilone-alone arm and 5.2 months (95% CI, 4.5 to 6.8

22 Ixabepilone and mitoxantrone doses were alternately esca

23 hese results suggest that the combination of ixabepilone and mitoxantrone is feasible and active in C

24 tors with histone deacetylase inhibitors and ixabepilone and MK1775 demonstrated excellent activity i

25 The pharmacokinetics of ixabepilone and two of its chemical degradation products

26 ucing propensity of three drugs: paclitaxel, ixabepilone, and eribulin mesylate.

27 thilones in development, along with those of ixabepilone, are comparable with historical response rat

28 25 patients (32%; 95% CI, 14% to 50%) on the ixabepilone arm, and 11 of 23 (48%; 95% CI, 27% to 68%)

29 44 patients (48%; 95% CI, 33% to 64%) on the ixabepilone arm, and 31 of 45 patients (69%; 95% CI, 55%

30 ), fatigue (9%), and neuropathy (13%) on the ixabepilone arm, and neutropenia (29%), febrile neutrope

31 The MTD of ixabepilone as a 1-hour infusion every 3 weeks was estab

32 ant, or metastatic therapy were treated with ixabepilone at 6 mg/m2/d intravenously on days 1 through

33 s less neuropathy in mice than paclitaxel or ixabepilone at equivalent MTD-based doses.

34 Paclitaxel and ixabepilone, at their respective MTDs, produced signific

35 This randomized phase II study evaluated ixabepilone-based chemotherapy in stage IIIb/IV NSCLC, c

36 We evaluated ixabepilone (BMS-247550) in patients with metastatic hor

37 PURPOSE Ixabepilone (BMS-247550) is a microtubule-stabilizing ep

38 Ixabepilone (BMS-247550) is an epothilone analog that op

39 Ixabepilone (BMS-247550) is an epothilone B analog that

40 conducted to determine the response rate of ixabepilone (BMS-247550, National Cancer Institute (NCI)

41 onstrating improved PFS and response for the ixabepilone-capecitabine combination compared with capec

42 Ixabepilone clearance was 475 +/- 247 mL/min/m(2), volum

43 Ixabepilone demonstrated clear activity and a manageable

44 Ixabepilone did not improve PFS or OS in patients with b

45 Ixabepilone did not significantly improve overall surviv

46 Of 49 patients treated with 40 mg/m(2) ixabepilone during 3 hours, 35 (73%) had experienced dis

47 Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line che

48 nd 11 of 23 (48%; 95% CI, 27% to 68%) on the ixabepilone + EMP arm.

49 neuropathy (7%), and thrombosis (6%) on the ixabepilone + EMP arm.

50 45 patients (69%; 95% CI, 55% to 82%) on the ixabepilone + EMP arm.

51 The recommended dose of ixabepilone for phase II trials in solid tumors is 8 mg/

52 The recommended dose of ixabepilone for the initiation of phase II studies on th

53 ents treated with mitoxantrone 12 mg/m2 plus ixabepilone > or = 30 mg/m2, nine (43%) experienced > or

54 Ixabepilone has also been evaluated in combination with

55 Ixabepilone has demonstrated activity in patients with c

56 Ixabepilone has single-agent activity in these patients

57 rly demonstrate the activity of single-agent ixabepilone in both taxane-untreated and taxane-treated

58 Multiple phase II trials evaluating ixabepilone in different populations of patients with me

59 To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (M

60 onal phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (M

61 II evaluation of the efficacy and safety of ixabepilone in patients with recurrent or persistent pla

62 acy and tolerability results demonstrated by ixabepilone in this study warrant its continued developm

63 ial, we evaluated the efficacy and safety of ixabepilone in women with metastatic and locally advance

64 the microtubule-binding drugs paclitaxel and ixabepilone induce more severe neuropathy in mice relati

65 Serious ixabepilone-induced neuropathy was relatively rare on th

66 Ixabepilone is a tubulin-inhibiting agent with low susce

67 Ixabepilone is an epothilone B analog that binds to micr

68 Ixabepilone is the first epothilone analogue to receive

69 ive analysis of the effects of epothilone B, ixabepilone (IXEMPRA(TM)), laulimalide, and peloruside A

70 ar as possible to the adult phase I trial of ixabepilone on the same schedule.

71 We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab

72 atients with chemotherapy-naive advanced BC, ixabepilone once per week was inferior to paclitaxel, an

73 actor, in advanced NSCLC treated with either ixabepilone or paclitaxel platinum-based doublets.

74 ta3T in differentiating clinical activity of ixabepilone- or paclitaxel-containing regimens.

75 ed to the antitubulin cancer drugs eribulin, ixabepilone, paclitaxel, or vinorelbine at MTDs.

76 estimated at $60,900 for patients receiving ixabepilone plus capecitabine and $30,000 for patients r

77 Ixabepilone plus capecitabine demonstrates superior effi

78 ught to determine whether the combination of ixabepilone plus capecitabine improved overall survival

79 Ixabepilone plus capecitabine prolonged progression-free

80 rial, we evaluated the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone

81 This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone

82 positive, 52; beta3T negative, 43) received ixabepilone plus carboplatin; 96 patients (beta3T positi

83 tandard dose-escalation phase, with doses of ixabepilone ranging from 7.4 to 65 mg/m2.

84 who were previously treated with paclitaxel, ixabepilone showed modest activity of limited duration a

85 oliferative concentrations of paclitaxel and ixabepilone significantly inhibited the anterograde tran

86 ared the effects of the drugs paclitaxel and ixabepilone that bind along the lengths of microtubules

87 meaningful durable response to single-agent ixabepilone therapy.

88 increased in tumor biopsies performed after ixabepilone therapy.

89 Addition of ixabepilone to capecitabine adds approximately $31,000 t

90 on-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.

91 The estimated gain in life expectancy with ixabepilone was 1.96 months (95% CI, 1.36 to 2.64 months

92 Ixabepilone was administered at 6 mg/m(2)/d intravenousl

93 Ixabepilone was evaluated for efficacy and safety in a p

94 Median PFS for paclitaxel was 11 months, ixabepilone was inferior to paclitaxel (PFS, 7.4 months;

95 administration of eribulin, vinorelbine, and ixabepilone, we observed delayed recovery after paclitax

96 y, pharmacokinetics, and pharmacodynamics of ixabepilone when administered as a 1-hour infusion every

97 y, these results suggest that paclitaxel and ixabepilone, which bind along the lengths and stabilize

98 Ixabepilone, with or without estramustine phosphate, is